Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.InSite Vision has signed its first international licensing and distribution agreement outside of North America for the company's AzaSite with Shin Poong Pharm Seoul, Korea. Under the terms of the agreement, Shin Poong Pharm will be responsible for securing regulatory approval and conducting the subsequent marketing of AzaSite in Korea.
Subscribe to our email newsletter
Under the terms of the agreement, InSite grants exclusive rights to Shin Poong to commercialize AzaSite (azithromycin ophthalmic solution) 1% for bacterial conjunctivitis treatment in Korea. Shin Poong will also be responsible for securing regulatory approval of AzaSite in Korea. In exchange, Shin Poong will pay InSite upfront and regulatory milestone payments and a double-digit royalty on net sales of AzaSite in Korea, if approved by regulatory authorities. InSite Vision will be responsible for providing manufactured product.
Kumar Chandrasekaran, president and CEO of InSite, said: “With Shin Poong’s experience and success in marketing in-licensed products in this rapidly growing Asian market, they are well-positioned to become InSite Vision’s commercial partner for AzaSite market development in Korea. As we build our international partner network for AzaSite products, Shin Poong represents the type of established market commitment and leadership necessary to assure commercial success for AzaSite in growing international markets.”